Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone267-440-4200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.48 million
Profitability
Miscellaneous
Employees281
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.02. The biopharmaceutical company earned $0.14 million during the quarter, compared to analysts' expectations of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 142.10%. During the same quarter last year, the firm earned ($0.07) EPS. View Inovio Pharmaceuticals' Earnings History.
When is Inovio Pharmaceuticals' next earnings date?
What price target have analysts set for INO?
5 analysts have issued 1-year price objectives for Inovio Pharmaceuticals' stock. Their predictions range from $3.62 to $13.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $7.32 in the next year. This suggests a possible upside of 191.8% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.
What is the consensus analysts' recommendation for Inovio Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property." (6/11/2019)
- 2. According to Zacks Investment Research, "Inovio’s earnings and revenues missed estimates in the first quarter of 2019. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares have underperformed the industry year to date." (5/28/2019)
- 3. Maxim Group analysts commented, "Inovio and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting." (4/3/2019)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
Media coverage about INO stock has trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Inovio Pharmaceuticals.
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Cerus (CERS), Axonics Modulation Technologies (AXNX), SurModics (SRDX), AngioDynamics (ANGO), MiMedx Group (MDXG), Intersect ENT (XENT), Antares Pharma (ATRS), Orthopediatrics (KIDS), OraSure Technologies (OSUR), SI-Bone (SIBN), Utah Medical Products (UTMD), Alphatec (ATEC) and GenMark Diagnostics (GNMK).
What other stocks do shareholders of Inovio Pharmaceuticals own?
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
- Mr. Peter D. Kies, Chief Financial Officer (Age 56)
- Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
- Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
- Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $2.51.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $248.57 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.View Additional Information About Inovio Pharmaceuticals.
What is Inovio Pharmaceuticals' official website?
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
